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Background: The reproducible nature of HIV-1 escape from HLA-restricted CD8+ T-cell responses allows the
identification of HLA-associated viral polymorphisms “at the population level” – that is, via analysis of cross-sectional,
linked HLA/HIV-1 genotypes by statistical association. However, elucidating their timing of selection traditionally requires
detailed longitudinal studies, which are challenging to undertake on a large scale. We investigate whether the extent
and relative timecourse of immune-driven HIV adaptation can be inferred via comparative cross-sectional analysis
of independent early and chronic infection cohorts.
Results: Similarly-powered datasets of linked HLA/HIV-1 genotypes from individuals with early (median < 3 months)
and chronic untreated HIV-1 subtype B infection, matched for size (N > 200/dataset), HLA class I and HIV-1 Gag/Pol/Nef
diversity, were established. These datasets were first used to define a list of 162 known HLA-associated polymorphisms
detectable at the population level in cohorts of the present size and host/viral genetic composition. Of these 162
known HLA-associated polymorphisms, 15% (occurring at 14 Gag, Pol and Nef codons) were already detectable via
statistical association in the early infection dataset at p ≤ 0.01 (q < 0.2) – identifying them as the most consistently
rapidly escaping sites in HIV-1. Among these were known rapidly-escaping sites (e.g. B*57-Gag-T242N) and others
not previously appreciated to be reproducibly rapidly selected (e.g. A*31:01-associated adaptations at Gag codons
397, 401 and 403). Escape prevalence in early infection correlated strongly with first-year escape rates (Pearson’s
R = 0.68, p = 0.0001), supporting cross-sectional parameters as reliable indicators of longitudinally-derived
measures. Comparative analysis of early and chronic datasets revealed that, on average, the prevalence of
HLA-associated polymorphisms more than doubles between these two infection stages in persons harboring the
relevant HLA (p < 0.0001, consistent with frequent and reproducible escape), but remains relatively stable in
persons lacking the HLA (p = 0.15, consistent with slow reversion). Published HLA-specific Hazard Ratios for
progression to AIDS correlated positively with average escape prevalence in early infection (Pearson’s R = 0.53,
p = 0.028), consistent with high early within-host HIV-1 adaptation (via rapid escape and/or frequent polymorphism
transmission) as a correlate of progression.
Conclusion: Cross-sectional host/viral genotype datasets represent an underutilized resource to identify
reproducible early pathways of HIV-1 adaptation and identify correlates of protective immunity.
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HIV-1 escape from Human Leukocyte-Antigen (HLA)
class I-restricted CD8+ T-lymphocytes (CTL) occurs in
a broadly predictable manner based on the HLA alleles
expressed by the host [1]. Reversion of escape mutations,
usually to consensus, upon HIV-1 transmission to an
individual lacking the restricting HLA also occurs re-
producibly in many [2-5], though not all [6-8], cases.
The reproducible nature of viral adaptation allows us
to identify HLA-associated polymorphisms in HIV-1
(that is, viral polymorphisms that are significantly over- or
under- represented among persons expressing a given
HLA allele) “at the population level” (that is, via the ana-
lysis of cross-sectional, linked HLA/HIV-1 genotypes via
statistical association approaches that additionally correct
for various potential confounders [9-12]). Such studies are
normally undertaken in chronic infection, as the virus
has undergone a majority of its within-host adaptation
by this stage. For example, a recent population-level
study of >1800 chronically HIV-1 subtype B-infected
persons identified over >2000 HLA-associated polymor-
phisms across HIV-1, with a majority occurring in Gag,
Pol and Nef [11].
Though HLA-associated polymorphisms in HIV-1 can
be identified using cross-sectional approaches, their tim-
ing of selection cannot be directly determined by these
methods. Rather, temporal information is ideally estab-
lished via detailed longitudinal study of untreated indi-
viduals recently infected with HIV-1 (e.g.: [2,3,13-19]).
However, identifying large numbers of recently-infected
persons is challenging. Another consideration is that,
given the current evidence and clinical recommenda-
tions supporting HIV-1 treatment initiation in early in-
fection [20], prospective longitudinal observational study
of untreated HIV-1 infection may no longer be feasible
nor ethical moving forward.
As such, cross-sectional pretreatment host/viral geno-
type datasets from individuals at different HIV-1 infec-
tion stages enrolled in established (or future) cohorts
could potentially provide alternate data sources to infer
the extent and time course of immune-driven HIV-1
adaptation, including the earliest events post-infection,
using population-level approaches. Though such ap-
proaches have been investigated [21,22], they remain
underutilized in this context. Notably, population-level
approaches offer one key advantage in that - by defin-
ition - they specifically identify HIV-1 adaptations that
occur reproducibly in persons expressing the restricting
HLA [21] (as opposed to longitudinal studies that
characterize immune escape dynamics in individual
persons, but cannot elucidate the extent to which such
pathways are shared between persons, e.g. [3,17-19]).
As such, population-level studies may be particularly
useful in identifying the HLA-restricted CTL escapemutations that are most rapidly and reproducibly
selected following HIV-1 infection.
In an attempt to achieve these goals, we undertook a
proof-of-concept study that compared the prevalence of
known HLA-associated polymorphisms in HIV-1 Gag,
Pol and Nef [11] in identically-sized cross-sectional
early and chronic infection cohorts that were matched
as closely as possible for their HLA allele distributions
and their total HIV-1 diversity. Our main goals were:
1) to assess the utility of population-level approaches to
identify the most reproducibly rapid escape mutations in
HIV-1; 2) to estimate the extent of escape and reversion
between early and chronic infection; and 3) to investigate
whether features related to population-level early im-
mune escape signal can discriminate protective from
non-protective HLA alleles.Results and discussion
Assembling early and chronic infection cohorts matched
for size, HLA and HIV-1 diversity
Our study sought to demonstrate that the extent, re-
producibility and relative timing (early versus later) of
HLA-driven escape in HIV-1 can be inferred via com-
parative analysis of independent cross-sectional host/
virus genotype datasets from different infection stages.
This strategy ideally requires cross-sectional datasets
that are identically powered with respect to host and
viral genetic diversity (i.e. datasets that mimic longitu-
dinal data as closely as possible, in that they differ only
with respect to infection stage of the participants). As
such, our first step was to assemble early and chronic
HIV-1 subtype B cohorts of identical size that were
matched as closely as possible for HLA class I allele
distribution and HIV-1 diversity. We did so by drawing
upon host and viral genotype data from early and
chronic infection cohorts in North America, Europe
and Australia (methods and [13,23-25]). Our final early
and chronic datasets comprised 221 Gag, 203 Pol and
219 Nef HIV-1 subtype B sequences per cohort, for
which linked HLA class I types were available. Early cohort
patients were recruited a median of 88 [IQR 63–120] days
following infection. All early and >75% of chronic patients
were antiretroviral naïve; the remainder were untreated at
time of sampling.
A total of 59 HLA class I alleles, classified at subtype-
level (4-digit) resolution, were observed at a frequency >1%
in the early and/or chronic cohorts; these comprised
17 HLA-A, 23 HLA-B and 19 HLA-C alleles (Figure 1).
Of these 59 alleles, the frequencies of 56 (94.9%) were
comparable between cohorts; only three alleles (HLA-
A*02:06, A*30:02 and B*39:01) exhibited significantly
different frequencies between cohorts (all p < 0.05;
0.08 < q < 0.33) (Figure 1A-C). As such, our early and
Figure 1 Early and chronic datasets are comparable with respect to host and viral diversity. The 17 HLA-A, 23 HLA-B and 19 HLA-C alleles
(total 56) observed at frequencies > 1% in the early and/or chronic datasets are displayed in Panels A-C, respectively. The early and chronic
datasets were comparable with respect to all HLA allele frequencies except HLA-A*02:06, A*30:02 and B*39:01 whose frequencies were higher in
the early cohort compared to the chronic cohort (denoted by “*” for p < 0.05 and “**” for p < 0.01, Fisher’s exact test). Note however that no
HIV-1 polymorphisms restricted by these three HLA class I alleles were assessed in the present study (see Figure 2 and Additional file 1). Panel D:
Unrooted maximum-likelihood phylogenies of early (left), chronic (middle) and combined cohort (right) Gag sequences, on a distance scale of
0.01 substitutions per nucleotide site. Mean patristic (pairwise) genetic distances between Gag sequences were comparable for early and chronic
cohorts; moreover, no gross cohort-specific clustering is observed in the combined phylogeny.
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spect to host HLA diversity.
HIV-1 Gag, Pol and Nef diversity was also generally
comparable between the two cohorts. Mean patristic
(pairwise) genetic distances between HIV-1 sequences
in early versus chronic datasets, measured in units of
substitutions per nucleotide site, were 0.076 (Standard
Deviation [SD] ± 0.011) versus 0.071 (SD ± 0.010) re-
spectively for Gag (Figure 1D left and middle panels),
0.057 (SD ± 0.008) versus 0.053 (SD ± 0.008) for Pol,and 0.119 (SD ± 0.018) versus 0.120 (SD ± 0.021) for Nef
(not shown). Moreover, no gross inter-cohort segrega-
tion was observed in a combined HIV-1 Gag phylogeny
(Figure 1D, right), indicating that neither cohort was
dominated by large epidemiologically linked clusters
nor exhibited evidence of recent descent from distinct
ancestors. Together, these data suggest that our early
and chronic datasets are similarly powered with respect
to host and viral genetic diversity, and thus differ only
with respect to infection stage.
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investigation in cohorts of the present size and
composition
A total of 453 HLA-associated polymorphisms in Gag/
Pol/Nef had previously been identified at q < 0.05 in an
independent cohort of N > 1800 individuals with chronic
HIV-1 subtype B infection [11], which contained no over-
lap with the cohorts studied here. These HLA-associated
polymorphisms comprise “adapted” associations (HIV-1
amino acids significantly over-represented in the presence
of the HLA allele in question) as well as “nonadapted”
associations (HIV-1 amino acids significantly under-
represented in the presence of the HLA allele). For ex-
ample, at Gag codon 242 the nonadapted amino acid
associated with HLA-B*57:01 is the subtype B consensus
“T” whereas the B*57:01 adapted form is “N”, denoted as
“B*57:01-Gag-T242N”. The cohort wherein these HLA-
associations were originally defined however [11] was
more than seven times larger than the cohorts presently
studied. Therefore, we do not have sufficient statistical
power to interrogate all of them in the present study. As
such, our next step was to define, from the published list
[11], the subset of known HLA-associated polymorphisms
that is appropriate for study in cohorts of the present size
and host/viral genetic composition.
Theoretically, if all immune escape mutations, once se-
lected, persisted for the remainder of the host’s lifetime,
and if we had achieved perfect genetic matching between
our early and chronic cohorts, then we could define an
appropriate subset of HLA-associated polymorphisms by
interrogating our chronic cohort for the presence of these
N = 453 known HLA-associated polymorphisms. Those
detectable at the population level in chronic infection,
a stage when a majority of within-host adaptation has
already occurred, would represent an appropriate sub-
set for study in cohorts of the present size. Thus we
first interrogated our chronic cohort for the presence
of these 453 published HLA-associated polymorphisms
using statistical association with phylogenetic correc-
tion (see Methods and [12,26]), and in doing so identified
157 (35%) “adapted” and “nonadapted” HLA associations
at p < 0.01 (corresponding to q < 0.01 in this analysis)
(Figure 2 and Additional file 1). These comprised 54, 52
and 51 HLA-associated polymorphisms in Gag, Pol and
Nef respectively.
However, if genetic matching of early and chronic co-
horts was imperfect, and/or if immune escape muta-
tions occasionally arose transiently during infection,
then defining HLA-associated polymorphisms based on
the chronic cohort only could potentially lead us to
miss some associations. Thus, we interrogated our early
cohort for this same list of published HLA-associated
polymorphisms using identical methods. In doing so we
identified an additional 5 HLA-associated polymorphismsat p < 0.01, two occurring at Gag codon 401 and one each
occurring at Nef codons 38, 102 and 133, that had not
been identified in the chronic analysis (Figure 2 and
Additional file 1).
We therefore took the union of these results, totaling
N = 162 HLA-associated polymorphisms, as our defin-
ition of known HLA-associated polymorphisms appro-
priate for cohorts of the present size and composition
(Figure 2 and Additional file 1). To further validate this
subset, we applied a published phylogenetically-corrected
interaction test (see Methods and [12,27]) to compare the
strengths of selection of these individual HLA-associated
polymorphisms in early versus chronic cohorts. Given that
within-host HIV-1 adaptation increases over the infection
course via the selection of immune escape mutations, we
would expect higher strengths of association between the
restricting HLA and the HIV-1 polymorphism at later ver-
sus earlier stages: indeed, of the 162 HLA-associated poly-
morphisms studied, the strengths of 101 (62%) of them
differed significantly (p < 0.01, q ≤ 0.1) between early and
chronic infection (Additional file 1). Note also that none
of the N = 162 polymorphisms were restricted by the three
HLA alleles (A*02:06, A*30:02 and B*39:01) whose fre-
quencies differed significantly between cohorts. All down-
stream analyses therefore focused on this list of N = 162
HLA-associated polymorphisms.
Fifteen percent of known HLA-associated polymorphisms
are already detectable at the population level in early
infection
Our first objective was to assess the extent of population-
level signal for HLA-driven escape in early HIV-1 infec-
tion. Of the N = 162 HLA-associated polymorphisms
identified for study, 24 (15%), occurring at 14 unique
codons in Gag, Pol and Nef, were detectable at the popu-
lation level in the early cohort at a threshold of p ≤ 0.01
(Table 1). In total, these 24 associations comprised 16%
of those investigated in Gag (9 of 56), 6% of those inves-
tigated in Pol (3 of 52) and 22% of those investigated in
Nef (12 of 54).
As expected, among these were escape mutations
known or previously observed to occur in the first year
of infection, including B*57:01 Gag-T242N, B*51:01
RT-I135X and Int-L28I, C*03:04 Nef-V85L, A*11:01
Nef-K92R and A*24:02 Nef-Y135F [2,13,16,18,19,21,28].
Our findings therefore provide proof-of-concept that the
most consistently rapid host adaptations in HIV-1 can be
identified using cross-sectional methods. It is notable that,
by < 3 months post-infection, the magnitude of statistical
association between certain HLA alleles and their associ-
ated viral polymorphisms is already very high, and in some
cases not significantly different from their magnitudes
of association in chronic infection. For example, the
Odds Ratio [OR] of association between B*57 and
Figure 2 HLA-associated polymorphisms detectable at the population level in cohorts of the present size and genetic composition.
Gag, Pol and Nef “immune escape maps” indicate the codon location, specific amino acid residues and HLA restrictions of the N = 162 known
HLA-associated polymorphisms detectable at the population level in cohorts of the present size and host/viral genetic composition. “Nonadapted”
amino acids (those under-represented in the presence of the HLA allele) are blue; these represent the “immunologically susceptible” form for the
HLA allele in question (and usually represent the subtype consensus residue). “Adapted” amino acids (those over-represented in the presence of
the HLA allele) are red; these represent the HLA-associated “escape variant”. Adapted and Nonadapted associations are counted independently; in
most cases both forms are detectable at the population level at a given p-value threshold (e.g. at Gag codon 242, “T” and “N” represent the
B*57:01 – associated nonadapted and adapted forms, respectively), whereas in other cases only one of the two forms is detectable at a given
threshold (e.g. at Gag codon 12, “E” represents the B*49:01-associated nonadapted form but no specific adapted form is detected at this threshold).
Asterisks (*) and italicized text denote the five HLA-associations at Gag codons 401 and Nef codons 38, 102 and 133 that were defined via detection in
the early cohort at p < 0.01, but were p≥ 0.01 in the chronic cohort. Note that HIV-1 RT genotyping was performed for codons 1–400 of this protein
only (the remainder of RT is colored gray). Subsequent analyses focused on this list of HLA-associated polymorphisms.
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pared to 151 (p = 5 × 10−16) in chronic infection, which,
though stronger during the latter stage, does not represent
a statistically significant difference (inter-cohort com-
parison p = 0.3) (Table 1). This observation underscoresthe rapid and highly reproducible nature of certain
HLA-driven within-host adaptations in HIV-1, where,
for certain mutations such as Gag-T242N, escape
(and by extension our ability to detect this associ-
ation via population-level methods) is already near
Table 1 HLA-associated polymorphisms detectable at the population level in early HIV-1 infection
Protein HLA HIV
polymorphisma
Early infection Chronic infection CD8+ epitope* p-value
(early vs. chronic)dOdds Ratiob p-valuec Odds Ratiob p-valuec (HIV codon coordinates)
Gag B*57:01 T242N 33 3 × 10−9 151 6 × 10−17 TSTLQEQIGW (240–248) 0.3
C*07:04 M378x 3.6 0.006 3.5 0.0002 IMMQRGNF (377–383)* 0.7
A*31:01 K397R 6.2 1 × 10−7 83 8 × 10−10 CGKEGHIAR (395–403) 0.5
A*31:01 I401L 5.1 0.005 1.98 0.01 CGKEGHIAR (395–403) 0.2
A*31:01 R403K 1.5 0.007 ~41 1 × 10−7 CGKEGHIAR (395–403) 0.002
Pol (RT) B*51:01 I135x 2.1 0.004 25 5 × 10−11 TAFTIPSI (128–135) 0.0001
Pol (Int) B*51:01 L28I 16 0.009 5 7 × 10−5 LPPIVAKEI (28–36) 0.2
Nef B*37:01 E38D 13 0.006 ~24 0.002 LEKHGAIT (37–45)* 0.2
C*03:04 V85L 2.4 0.002 4 0.0002 AALDLSHFL (83–91) 0.6
A*11:01 K92R 5.3 0.009 8.4 4 × 10−6 AVDLSHFLK (84–92) 0.2
C*03:04 H102x 3.2 0.001 ~1 0.25 none 0.1
A*23:01 F143Y 8.4 0.01 852 5 × 10−8 RYPLTFGWCF (134–143) 0.1
B*57:01 x133I 6 0.004 1.4 0.29 YTPGPGIRY (127–135) 0.2
A*24:02 Y135F 2.3 0.004 15 2 × 10−21 RYPLTFGW (134–141) 0.0005
aA total of 24 associations, occurring at 14 unique HIV-1 codons, are listed. The total 24 is reached because HLA-associated nonadapted and adapted forms are
counted individually (e.g. B*57:01-Gag-T242N comprises two associations– the nonadapted T and the adapted N). Cases where a specific non-adapted or adapted
form was not detected in early infection are denoted by a lowercase “x” (e.g. B*51:01-RT-I135x). Polymorphisms in bold represent associations detectable in both
early and chronic infection at p ≤ 0.01; those italicized represent associations detectable in only the early cohort with p < 0.01.
bWhere both nonadapted and adapted forms for a given HLA are identified, the maximum absolute Odds Ratio is shown.
cWhere both nonadapted and adapted forms for a given HLA are identified, the lowest p-value is shown. Note the chronic p-value for B*37:01-Nef-E38D refers to
its nonadapted (E38x) form; the p-value for the adapted (x38D) form at this stage is 0.07.
*Bioinformatically predicted CTL epitopes are denoted by asterisks (*); the remainder are published (http://www.hiv.lanl.gov/content/immunology/tables/tables.html).
Bold letters indicate the position within the epitope where the HLA-associated polymorphism occurs. Note the C*03-restricted AALDLSHFL epitope has been published
in its C*03-adapted form.
dFor each HLA-associated polymorphism in the table, its strength association in early versus chronic infection was compared using a previously-described
phylogenetically-corrected interaction test (see Methods and [12,27]). The p-values of these comparisons are listed in this column.
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post-infection.
Of note, HLA-associated HIV-1 polymorphisms with
strong early population-level escape signal also included
understudied viral sites. Notable among these were
A*31:01-associated polymorphisms at Gag codons 397,
401 and 403, the first of which represented the second
strongest p-value detected in the early cohort (Odds
Ratio = 6.2, p = 1 × 10−7, Table 1). These associations
are located within the novel A*31:01-restricted CR9
CD8+ epitope originally characterized via detailed lon-
gitudinal analysis of a single HIV-1 subtype B-infected
individual [18,19]. By definition, population-level stud-
ies identify viral adaptations that occur reproducibly in
persons expressing the restricting HLA; as such, the
present results extend those of the original individual-
level study [18] by indicating that escape within CR9 is
both rapid and highly consistent in HLA-A*31:01-ex-
pressing persons. By extension, a lack of population-
level early escape signal does not necessarily mean that
a given site never escapes early: rather, it indicates that
a given site does not reproducibly escape early (or at
least does not do so to an extent that achieves statis-
tical significance in a dataset of the present size). For
example, very rapid (<30 days) escape was previouslydocumented within the A*01-restricted GY9 epitope
(Gag codons 71–79) in two HIV-1 subtype C-infected
persons [19], but no evidence of reproducible early escape
Gag codon 79 in A*01-expressing persons was observed in
our early dataset, suggesting that rapid A*01-driven escape
at this position is atypical in HIV-1 subtype B.
Taken together, population-level analyses extend those
of individual-level studies by identifying escape mutations
that are rapidly and reproducibly selected across patients.
Our observation that 15% of known HLA-associated
polymorphisms, notably those in Nef and Gag, are already
detectable < 3 months post-infection, underscores the pre-
dictable and rapid nature of HIV-1 adaptation despite each
individual’s unique combination of host HLA and trans-
mitted virus genetics. Further, the detection of substantial
population-level escape signal within unknown or under-
studied CD8+ epitopes in HIV-1 (Table 1) argues for con-
tinued efforts to map novel epitopes commonly targeted
during this critical infection stage.
Can population-level approaches identify transient early
escape pathways?
Recent longitudinal studies have revealed that immune
escape is often characterized by the initial appearance of
transient mutant forms that often retain some ability to
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then drive the selection of more effective escape variants
that ultimately become fixed within the host [3,17,18]. If
such “transient” escape pathways are reproducible across
hosts, we wondered whether population-level approaches
could theoretically be used as exploratory tools to identify
them. If so, we reasoned that such transient escapes would
display stronger population-level escape signal in early
compared to chronic infection (since, in some persons,
the early variant would be subsequently replaced with an-
other, thereby reducing population-level signal in later
stages). Although our inter-cohort comparative analysis
revealed no HLA-associated polymorphisms that dis-
played significantly stronger signal in early versus chronic
infection (Additional file 1 and data not shown), we were
nevertheless intrigued by the five HLA-associated poly-
morphisms in Gag and Nef that exhibited population-level
escape signal of p < 0.01 in our early cohort but p ≥ 0.01 in
the chronic cohort (Table 1), suggesting these as possible
transient escape pathways.
Indeed, analysis of available longitudinal bulk plasma
HIV-1 RNA Nef sequences from seven B*57:01 express-
ing individuals identified one case where an individual
harbored the Nef-133I adapted mutation at the earliest
sampled timepoint 30 days post-infection, which was re-
placed by V at 86 days post-infection and then by a mix-
ture of I/V at 228 days-post infection (Table 2). Similarly,
analysis of available bulk plasma Gag sequences from
seven A*30:01 expressing persons identified one case
where an individual harbored the adapted Gag-401 LTable 2 Examples of possible transient early HLA-driven esca
early versus chronic infection
HLA-associated HIV-1 polymorphism Patient HLA
A*31:01-Gag-I401L A0301/3101 B4403/3503 C0401/0
B*57:01-Nef-x133I A2402/2902 B4403/5701 C0602/1
A small number of HLA-associated polymorphisms, including A*31:01-Gag-I401L an
versus chronic infection (see Table 1). Though these differences were not statistical
they could represent potential examples of transient escape. In support of this hypo
harbored the HLA-associated adapted variant at a given HIV-1 codon at the earliest
(and/or a mixture of the two), consistent with transient early escape at these positiovariant at the earliest timepoint post-infection, that was
subsequently replaced by a non-adapted form (and/or a
mixture of the two) within a year of infection. In both of
these cases the association is located at position 7
within the epitope, which is consistent with transient
early escape mutations representing incomplete TCR
repertoire escape variants [18,29]. The idea that escape
mutations, once selected, may not always persist for the
lifetime of the host is also supported by within-host re-
version of certain escape mutations in very advanced
disease [22]. We thus cautiously interpret the data to
suggest that cross-sectional approaches could theoretically
be used to identify reproducible HLA-driven adaptations
that represent “transient” early escape variants in some in-
dividuals, though such findings would require validation
in independent cohorts, as well as experimentally.
Escape prevalence in early infection correlates with
longitudinal first-year escape rates
Another objective was to investigate to what extent
cross-sectional data could be used to infer the extent
and time course of immune-driven HIV-1 adaptation. As
such, we first wished to demonstrate that early escape fre-
quencies calculated cross-sectionally predict rates of im-
mune escape calculated longitudinally. Published first-year
rates of escape were available for 27 optimally-described
CD8+ T-cell epitopes [13] which contained one or more
HLA-associated polymorphisms investigated in the present
study. For example, the estimated first year escape rate
for the Gag-TW10 epitope (Gag240–249) is 38.36% perpe at HIV codons with stronger population-level signal in
Days post-infection Bulk plasma seq. Adapted to HLA?
401 143 L yes
226 L yes
309 I no
485 I/L partial
563 I no
683 I/L partial
601 30 I yes
31 I yes
60 I yes
86 V no
123 V no
228 [I/V] partial
361 [I/V] partial
396 [I/V] partial
d B*57:01-Nef-x133I, showed stronger population-level escape signal in early
ly significant (Table 1, last two columns), we nevertheless hypothesized that
thesis, the above table provides examples of two cases where a patient
timepoint post-infection, that subsequently give way to a non-adapted form
ns in these patients.
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Gag-T242N mutation among B*57-expressing persons
in our early dataset is 67% (Figure 3). As expected, lon-
gitudinal first-year CD8+ epitope escape rates correlated
significantly with HIV-1 polymorphism prevalence among
persons expressing the relevant HLA in our early infection
dataset (Pearson’s R = 0.68, p = 0.0001; Figure 3). Because
~40% of the patients in the present early infection cohort
were included in the published longitudinal study [13], we
re-analyzed our data with these overlapping patients re-
moved, and observed that the correlation remained strong
(Pearson’s R = 0.55, p = 0.0035, not shown). This supports
HLA-associated escape mutation prevalence calculated
cross-sectionally at < 3 months post-infection as a reliable
surrogate marker of first year escape rates calculated
longitudinally.Figure 3 Escape prevalence in early infection correlates with
longitudinal first-year escape rates. A total of 27 HLA-associated
polymorphisms in Gag (orange), Pol (green) and Nef (purple)
occurring within optimally defined CTL epitopes, for which first-year
epitope-specific rates of escape were previously published [13], were
investigated. A significant positive correlation is observed between
the proportion of persons expressing the restricting HLA and
harboring the relevant polymorphism (“proportion escaped”) in early
infection and the published first-year epitope escape rate, providing
proof-of-concept that the relative timecourse of early escape in HIV-1
can be inferred using cross-sectional methods. In the case where a
given epitope contained multiple HLA-restricted polymorphic sites,
the site exhibiting the maximum “proportion escaped” was used.
For figure clarity, only a subset of well-known epitopes are labeled
for interest.Inferring the extent of host adaptation via comparative
analysis of cross-sectional data from early and chronic
infection
We next wished to use our cross-sectional early and
chronic cohorts to quantify the extent of HLA-driven
escape occurring between these two infection stages.
For this analysis, we specifically defined “escape” as the
specific adapted viral form associated with a given HLA
allele at a given HIV-1 codon - for example, Gag 242 N
is the B*57:01-associated adapted form at this position.
This adapted list comprised N = 74 HLA-associated
polymorphisms (25, 24, and 25 in Gag, Pol and Nef re-
spectively) (Figure 2 and Additional file 1). We calcu-
lated the prevalence of each of these polymorphisms in
persons expressing the relevant HLA allele in our early
versus chronic cohorts, thus allowing us to estimate the
extent of within-host HIV-1 adaptation between these
two stages. Overall, the median “percentage escaped”
(defined as the % of individuals expressing the relevant
HLA and harboring the HIV-1 polymorphism of inter-
est) was 23.8% [Interquartile range (IQR) 5.3-44.4%] in
early infection versus 55.1% [IQR 28.4-73.0%] in chronic
infection (p < 0.0001; Figure 4A). This indicates that, on
average, escape prevalence in persons expressing the
restricting HLA allele more than doubles between these
infection stages. Breaking the analysis down by HIV-1
protein, the median early versus chronic escape preva-
lence was 23.5% [IQR 15.1-49.7%] vs. 55.6% [IQR 29.7-
85.7%] in Gag, 11.3% [IQR 1.2-33.3%] vs. 50.5% [IQR
25.2-69.2%] in Pol, and 31.3% [7.5-63.0%] vs. 54.6%
[21.4-73.3%] in Nef (all p ≤ 0.001, not shown). This is
consistent with early escape occurring predominantly in
Gag and Nef [13,14,19], while escape in Pol is generally
slower but nevertheless approaches comparable levels
by chronic infection.
Though summary statistics are informative, individual
polymorphisms differ widely in their timing and extent of
selection over the infection course. For this reason, details
on polymorphism prevalence in persons expressing vs. not
expressing the relevant HLA in early and chronic infec-
tion, along with their statistical measures of association,
are provided in the Additional file 1. We highlight some
examples here. First, for a substantial minority of poly-
morphisms (notably those in Table 1), escape is rapid,
reproducible and largely complete within < 3 months
post-infection. For example, 67% of B*57:01-expressing
individuals already harbored Gag-242 N in early infec-
tion, a proportion that increased to 83% in the chronic
phase (Figure 4A). Noting that Gag-242 N frequency was
only 5.8% among persons lacking B*57:01 in early infec-
tion (Additional file 1), these results are consistent with
escape having already occurred in over two-thirds of B*57-
expressing persons by < 3 months post-infection [2,13],
with an additional minority escaping somewhat later.
Figure 4 Estimated extent of escape and reversion between early and chronic infection. Panel A: For each of the specific HLA-associated
“adapted” (escaped form) HIV-1 polymorphisms investigated (N = 74 total), the proportion of persons expressing the restricting HLA and harboring
the relevant polymorphism (“proportion escaped”) in early versus chronic infection are depicted as linked pairs. The data indicate that, on average,
escape prevalence in persons expressing the restricting HLA allele more than doubles between early and chronic infection. Panel B: The N = 74
HLA-associated “adapted” polymorphisms are broken down in terms of their relative timeline of escape (“earlier” vs. “later”, where the former is
defined as population-level signal of p < 0.05 in early infection) as well as their relative prevalence/transmission frequency in the population
(“lower” vs. “higher”, where the former is defined as <30%). The size of each pie reflects the proportion of polymorphisms in each category, while
the “pie slices” denote the breakdown of polymorphisms by HIV-1 protein (orange, green and purple for Gag, Pol and Nef respectively). Summary
statistics and examples of HLA-associated polymorphisms in each category are also provided. Panel C: The proportion of persons harboring an
HLA-associated adapted HIV-1 polymorphism in the absence of the restricting HLA allele in early versus chronic infection is shown. The data are
generally consistent with slow reversion of many transmitted escape mutations [7,14,34]. In all panels, polymorphisms are colored by HIV-1
protein: Gag (orange), Pol (green) and Nef (purple); those mentioned in the text are labeled.
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eral population (5.8% among B*57:01-negative persons
and ~1% among persons lacking an allele belonging to
the B58 supertype), other polymorphisms are quite
prevalent in circulation, but are nevertheless signifi-
cantly enriched among HLA-expressing persons in early
infection (Figure 4A). In this case, their high early
prevalence is attributable to both frequent transmission
and reproducible early escape. For example, both the
A*31:01-associated Gag-403 K and C*03:04-associated
Nef-85 L polymorphisms are observed at >40% preva-
lence in HIV-1 subtype B sequences, but their preva-
lence is ~55% and ~72% respectively among persons
expressing the relevant HLA < 3 months post-infection
(Odds Ratios 1.5 and 2.4 respectively, p < 0.01, Table 1
and Additional file 1). The observation that population-
level approaches are capable of detecting strong escape
signals despite high polymorphism background frequen-
cies has previously been demonstrated in high-powered
chronic infection cohorts [11]; the present study extends
this to demonstrate such signals can also be detected very
early in infection, in more modestly-powered datasets.
Overall, if one uses the original criterion of early
population-level statistical signal of p ≤ 0.01 to define
HIV-1 sites that predominantly escape early, 15% (11
of 74) of adapted polymorphisms fall into this category;using a more liberal threshold of p < 0.05, this increases
to 21.6% (16 of 74) (Figure 4B).
The remaining 78.4% (58 of 74) polymorphisms gener-
ally reproducibly escape later than 3 months following
infection (Figure 4B). It is important to note that later
escape can occur because CTL responses against these
regions generally arise later during infection (i.e. there is
no immune pressure on these epitopes in early infection),
or because CTL responses arise relatively early, but escape
does not reproducibly occur rapidly in a significant pro-
portion of individuals expressing the relevant HLA allele.
Among these later-escaping polymorphisms are those
whose population background (transmission) frequencies
are generally low, and those whose background fre-
quencies are generally high. The B*51:01-associated
Integrase-32I polymorphism at position 5 of the B*51-
restricted LI9 epitope (Integrase28–36) provides an ex-
ample of the former. In early infection, its frequency in
B*51:01-expressing persons is 5%, not significantly
different from background, but this rises to 64% by
chronic infection (Figure 4A and Additional file 1).
The LI9 epitope is known to be consistently targeted in
B*51-expressing persons early after infection [30,31].
The observation that this epitope ultimately escapes via
Int-32I in >60% of B*51:01-expressing persons suggests
this epitope is under strong, sustained and reproducible
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cape is likely explained by a combination of mutational/
fitness constraints and both intra-individual (“vertical”)
and inter-individual (“horizontal”) CD8+ T-cell immu-
nodominance hierarchies [19,32,33].
An example of a later-escaping polymorphism with high
population background frequency is B*44:02-Gag-312E. Lo-
cated at position 7 of the B*44:02-restricted AW11 epitope
(Gag306–317), it represents the HIV-1 subtype B consensus
residue at this codon. Its >60% frequency in both B*44:02
and non-B*44:02-expressing persons in early infection
reflects its high transmission frequency, rather than
early selection by B*44:02. Nevertheless, by chronic in-
fection, 83% of B*44:02-expressing persons harbored
Gag-312E, consistent with later escape (Figure 4A). A
full categorization of HLA-associated “adapted” polymor-
phisms in terms of “earlier” vs. “later” escaping (defined as
early p < 0.05 vs. p ≥ 0.05 respectively) and “lower” vs.
“higher” background (estimated transmission) frequency
(defined as <30% vs. p ≥ 30% respectively), is provided in
the Additional file 1. A graphic depicting the proportion
of HLA-associated polymorphisms in each of these cat-
egories, broken down by HIV protein, is provided in
Figure 4B.
The extent of reversion of HLA-associated polymor-
phisms over time can be similarly estimated by calculat-
ing their prevalence in persons lacking the relevant HLA
in the early versus chronic cohorts. The overall median
percentage of individuals harboring a given polymorph-
ism in the absence of the restricting HLA allele was
comparable in early (13.7% [IQR 4.9-34.2%]) and chronic
(14.9% [4.2-34.9%]) infection (p = 0.15; Figure 4C), consist-
ent with slow reversion reported for many polymorphisms
[7,14,21,34]. Note that inferred reversion frequencies merit
cautious interpretation in cases where polymorphisms are
selected by multiple alleles (e.g. the seemingly stable preva-
lence of Gag-147 L in A*25:01-negative individuals is likely
due in part to its selection by B*13:02 and B*57:01 [11], as-
sociations that were not investigated in the present study).
Nevertheless, results confirmed that HLA-B*57:01-Gag-
T242N reverts between early and chronic infection
(though RT-245E, Int-122I, Int-124N, or Nef-116N revert
slowly or not at all, as reported previously [2,21,35]).
The reversion analysis additionally revealed novel sites
of potential interest. For example, the early escaping
A*31:01-Gag 397R polymorphism (Table 1 and [18,19])
displayed evidence of reversion, suggesting that this
mutation may have a high fitness cost.
Host adaptation-related features distinguish protective
and non-protective HLA class I alleles
Lastly, we wished to identify adaptation-related features
that discriminate protective from non-protective HLA
alleles, defined here as their published hazard ratiosfor progression to AIDS [HR-AIDS] in natural history
studies [36]. Although the timecourse of viral escape is
influenced by complex factors including epitope immuno-
dominance hierarchies, strength of selection, mutational/
fitness constraints and transmitted virus characteristics
[17,19,34,37-40], we reasoned that HLA alleles that re-
strict polymorphisms that are already highly prevalent
in early infection (due to rapid escape and/or frequent
transmission) would be generally unfavorable for HIV-1
control. Thus, for all HLA alleles for which ≥2 adapted
polymorphisms were investigated in the present study
(N = 17 alleles total), we computed their mean “percent-
age escaped” in early infection. That is, we took the
prevalence of each of these adapted polymorphisms in
persons expressing the relevant HLA allele in our early
cohort (displayed in Figure 4A), and, for each HLA al-
lele, computed the mean of these values.
Consistent with our hypothesis, we observed a positive
correlation between an HLA allele’s average extent of
adaptation in early infection, and its HR-AIDS (Pearson’s
R = 0.53, p = 0.028; Figure 5A). Of note, HLA-B*57:01
appears as somewhat of an outlier, exhibiting higher
than expected escape prevalence in early infection given
its protective nature. We hypothesize that the reason
B*57 can maintain sustained HIV-1 control despite rapid
escape in some epitopes (Table 1 and [2,13,16,18,28]) is
because the early B*57-restricted CD8+ response often
simultaneously targets more than one epitope, notably
in p24Gag [31,41-43], where escape is accompanied by
fitness costs [44-46].
HLA-associated polymorphisms identified at the popu-
lation level mark viral sites under strong, reproducible
in vivo immune pressure by individual HLA alleles [11].
We thus further hypothesized that HLA alleles for which
escape was substantial (i.e. selected in a high proportion
of persons expressing the relevant HLA) but generally
delayed (i.e. selected post early-phase) would tend to be
more protective. As such, for the same set of HLA-
associated polymorphisms we computed their fold-
change in escape between early and chronic infection,
and calculated the mean of these values per HLA allele.
By this measure, alleles for which the majority of escape
had already occurred in early infection would exhibit
low subsequent fold-changes, whereas alleles selecting
escape mutations that generally occurred later in infec-
tion would exhibit fold-changes reflecting the extent of
selection pressure on these sites in persons expressing
the relevant HLA. Consistent with our hypothesis, we
observed an inverse correlation between an HLA allele’s
HR-AIDS and its average fold-increase in escape in chronic
versus early infection (Pearson’s R = −0.54, p = 0.025;
Figure 5B). Of note, B*27 appears as an additional out-
lier in this analysis, possibly due to escape in the critical
Gag-KK10 epitope requiring nearly a decade in some
Figure 5 Adaptation characteristics as correlates of HLA-associated progression risk. Colored dots denote individual HLA-A (red), HLA-B (blue)
and HLA-C (green) alleles for which ≥2 adapted polymorphisms were investigated in the present study (N = 17 alleles total). Each HLA allele’s Hazard
Ratio of progression to AIDS (x-axis) was derived from historic published seroconverter studies [36]. Panel A: For each HLA, the proportion of persons
expressing that allele and harboring the specific viral HLA-associated polymorphism in early infection was calculated as the mean of all HLA-associated
adapted polymorphisms investigated (y-axis). A significant positive relationship is observed between these two variables (Pearson’s R = 0.53, p = 0.028),
suggesting that in general, high early escape prevalence is a correlate of higher HLA-associated progression risk. Panel B: For each HLA, the mean
fold-increase in escape in chronic versus early infection was calculated from all HLA-associated adapted polymorphisms investigated (y-axis). A
significant inverse relationship is observed between these two variables (Pearson’s R = -0.54, p = 0.025), suggesting that in general, protective
alleles are those from which HIV-1 escape is substantial and reproducible, yet occurs on a delayed timescale.
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barrier [33,49].
Overall, our findings are consistent with a high early
burden of adaptation to host HLA (either via rapid escape
or frequent polymorphism transmission) as a correlate of
HLA-associated progression risk. Conversely, HLA alleles
from which HIV-1 escape is substantial and reproducible
yet occurs on a delayed timescale appears to be a correlate
of protection. Taken together with observations that pro-
tective HLA alleles contribute substantially to the total
HIV-specific CD8+ response in early infection [31,38], that
they impose broad selection pressures on HIV-1 [11]; and
that some CD8+ epitopes escape slowly despite sustained
CD8+ targeting [19,48], results suggest that the capacity
to exert consistent, substantial and sustained pressure,
ideally on multiple epitopes, from which the virus can only
escape on a relatively delayed timescale, is a correlate of
protection.
Some limitations of our study merit mention. Firstly,
our early and chronic datasets are relatively modestly
powered by association testing standards, so it was not
possible to examine all published HLA-associated poly-
morphisms in HIV-1 subtype B. Secondly, due to the
lack of information on duration of infection for chronic
patients, it is likely that the chronic cohort comprised
patients at a range of infection stages. Inclusion of some
chronic patients with less advanced infection could
underestimate the extent of escape at this stage. Finally,
although care was taken to match our early and chronic
datasets as closely as possible for HIV and HLA genetic
diversity and distribution, it is essentially impossible to
achieve perfectly matched datasets. As such, we cannotrule out small differences in statistical power between co-
horts, and therefore should interpret candidate “transient”
early escape results with some caution.Conclusions
In conclusion, our results provide proof-of-concept that
statistical association approaches can be applied to cross-
sectional host/viral genetic datasets to identify the most
rapidly selected HLA-associated polymorphisms in HIV-1
that are also reproducibly selected across patients. As such,
results from these types of population-level studies com-
plement those of individual-level longitudinal analyses that
cannot assess inter-patient reproducibility. Furthermore,
the extent and relative timing of individual escape events
(in terms of early versus later in the infection course) can
also be inferred from cross-sectional data. In particular, we
demonstrate that high escape prevalence in early infection
(either due to rapid selection and/or high transmission fre-
quency) is a correlate of HLA-associated progression risk
while reproducible later escape (a surrogate of consistent
immune selection on a given site in persons expressing
the relevant HLA) is a correlate of protection.
Given that longitudinal observational studies of untreated
persons are incompatible with current recommendations
for early HIV-1 treatment initiation [20] and treatment as
prevention [50], cross-sectional analyses of pretreatment
host/viral genotypes could provide relevant alternative tools
to advance our knowledge of HIV-1 adaptation, including
the earliest events post-infection. We suggest that studies
such as the present one be undertaken with expanded
cross-sectional cohorts, comprised of individuals at various
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subtypes.
Methods
Early and chronic infection cohorts
The early cohort was comprised of HIV-1 subtype B
infected patients recruited through various observa-
tional seroconverter studies including the Acute Infection
and Early Disease Research Program (AIEDRP) sites in
Boston and New York (USA), Sydney (Australia), a private
medical clinic in Berlin (Germany), and observational
cohort studies in Montreal and Vancouver (Canada)
[13,23,24]. Infection dates for the patients in the early
cohort were estimated as described in [13,23]. Briefly,
for patients with positive HIV RNA (>5,000 copies/ml)
or detectable serum p24 antigen but a negative HIV-1
enzyme immunoassay (EIA), 4 weeks were subtracted
from the negative EIA date. For patients with positive
EIA but negative/indeterminate Western blot, 6 weeks
were subtracted from the positive EIA date. For patients
with negative detuned EIA, 4 months were subtracted
from this date. For the remainder, infection dates were
estimated as the midpoint between the last negative and
the first positive HIV test. Clinical histories were incor-
porated into infection date estimates where available.
To maximize our power to detect HLA-associated
polymorphisms in the early infection stage, all available
early infection patients were included in the present
study. For each of these patients, the sample closest
to ~3-months following the estimated date of infection
was selected, yielding a median sampling distribution of
88 days [Interquartile Range 63–120 days] post-infection
for early samples. In contrast, the chronic cohort was as-
sembled from the baseline (pre-therapy) timepoint from a
total of more than 300 HIV-1 subtype B infected individ-
uals initiating antiretroviral therapy in British Columbia,
Canada, and untreated HIV-1 subtype B infected individ-
uals in Boston, USA [13,25]. Time since infection is un-
known for individuals in the chronic cohort, however the
median CD4 count at sampling was 250 [IQR 147–360]
cells/mm3 for this group. To create HIV-1 gene-specific
chronic infection datasets of equal size to the early cohort,
that were also matched as closely as possible for HLA
class I and HIV-1 diversity of the early cohort, chronic pa-
tients were selected from the total group using an iterative
process to achieve the closest matching of HIV-1 and
HLA distributions (Figure 1). All early and >75% of
chronic patients were antiretroviral naïve; the remainder
were untreated at time of sampling.
Ethics statement
All patients provided written informed consent. Ethical
approval was obtained through the institutional review
boards at the Massachusetts General Hospital, the BCCentre for Excellence in HIV/AIDS and Simon Fraser
University.
HIV-1 and host (HLA class I) genotyping
HIV-1 RNA was extracted from plasma using standard
methods. Gag, Pol (including protease, codons 1–400
of Reverse Transcriptase, and Integrase), and Nef were
amplified in separate nested RT-PCR reactions using
HIV-1 subtype B-specific primers. Amplicons were bulk-
sequenced bidirectionally on a 3130xl and/or 3730xl
automated DNA sequencer (Applied Biosystems). Chro-
matograms were analyzed using Sequencher v5.0 (Gene-
codes) or RECall [51] with nucleotide mixtures called if
the height of the secondary peak exceeded 25% of the
height of the dominant peak (Sequencher) or 20% of the
dominant peak area (RECall). HIV-1 sequences were con-
firmed as subtype B using the recombinant identification
program (RIP; http://www.hiv.lanl.gov/content/sequence/
RIP/RIP.html) and aligned to the HIV-1 subtype B refer-
ence strain HXB2. Phylogenetic trees were constructed
using PhyML [52] and visualized using FigTree (http://
tree.bio.ed.ac.uk/software/figtree/). Pairwise genetic dis-
tances were computed from newick treefiles using
PATRISTIC [53]. HLA class I typing was performed using
sequence-based methods [54] and imputed where neces-
sary to high resolution using a machine learning algorithm
([55]; http://research.microsoft.com/en-us/projects/bio/
mbt.aspx#HLA-Completion). HIV-1 sequences from co-
horts where REBs allow public sequence deposition have
been deposited in GenBank: accession numbers are Gag
(KJ869442 - KJ869609), Protease-RT (KJ869900 - KJ870015),
Integrase (KJ869610 - KJ869735), Nef (KJ869736 - KJ869899).
A full summary of polymorphism frequencies, broken
down by HLA allele carriage and infection stage is
provided as Additional file 1.
Definition and identification of HLA-associated
polymorphisms
The published reference list of N = 453 HLA-associated
polymorphisms in HIV-1 subtype B Gag, Pol and Nef
sequences was defined in an independent international
cohort of >1800 individuals chronically infected with
HIV-1 subtype-B using phylogenetically-informed methods
at q < 0.05 [11]. The cohort used to define these associa-
tions had no overlap with the early and chronic cohorts
studied here [11]. Briefly, to identify HLA-associated
polymorphisms in linked HIV/HLA datasets, maximum
likelihood phylogenetic trees (one per HIV-1 gene) are
constructed, and a model of conditional adaptation is
inferred for each observed HIV-1 amino acid at each
codon. The amino acid is assumed to evolve independ-
ently along the tree until it reaches the tips, represent-
ing the present host. Selection via host HLA-mediated
pressures and HIV-1 amino acid covariation is directly
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the individual’s HLA repertoire and covarying HIV-1
amino acids are used as predictors, and the bias is deter-
mined by the inferred possible transmitted sequences
(as inferred via reconstruction of the amino acid frequen-
cies at the penultimate internal nodes in the phylogeny)
[12]. Here, the null hypothesis is that the observed amino
acids at the tree tips are explained by the phylogeny only,
whereas the alternative hypothesis is that they are better
explained by the presence of a specific HLA (or covarying
HIV-1 amino acid) in the present host. To identify which
factors (HLA and/or HIV-1 covariation) contribute to
the selection pressure, a forward selection procedure is
employed where the most significant association is added
to the model in an iterative fashion, with p-values com-
puted using the likelihood ratio test. Statistical significance
is reported using q-values [56], the p-value analogue of
the false discovery rate (FDR). Q-values denote the ex-
pected proportion of false positives among results
deemed significant at a given p-value threshold; for ex-
ample, at q ≤ 0.05, we expect 5% of identified associa-
tions to be false positives.
HLA-associated polymorphisms are classified into two
categories: (1) “Adapted forms”, amino acids significantly
overrepresented in the presence of the HLA allele in
question, which represent the putative escape forms asso-
ciated with that HLA at that codon, and (2) “Nonadapted
forms”, amino acids significantly underrepresented in the
presence of the HLA allele in question, which represent
the immunologically susceptible form associated with that
HLA at that codon. In most cases, HLA-associated nona-
dapted forms represent the subtype consensus amino acid
while adapted forms represent polymorphic variants – but
exceptions exist.
To identify an appropriate subset of known HLA-
associated HIV-1 polymorphisms that are appropriate
for study in datasets of the present size (N ~ 200) and
host/viral genetic distribution, we interrogated our early
and chronic infection cohorts for these N = 453 pub-
lished polymorphisms [11] using the phylogenetically-
corrected methods described above. As described in the
results, this yielded a subset of N = 162 HLA-associated
polymorphisms detectable in our early and/or chronic
datasets (Figure 2 and Additional file 1).
Our analyses also featured comparisons of the
strength of selection of HLA-associated polymorphisms
between early and chronic cohorts, undertaken using a
previously-described phylogenetically-corrected inter-
action test [12,22,27]. Briefly, we took the union of all
HLA-associated polymorphisms detectable at the popu-
lation level in either the early or chronic cohorts (N = 162).
For each association on the list, we constructed a
phylogenetically-corrected logistic regression model using
the restricting HLA as a predictor. Using a likelihoodratio test, we compare this model to a more expressive
one that includes an additional interaction term that as-
signs “1” if the individual expresses the restricting HLA
allele and is in the chronic cohort, or “0” otherwise. This
allows us to obtain a p-value testing the null hypothesis
that HLA-associated selection at that site is not signifi-
cantly different in early versus chronic cohorts.
Statistical analyses
Fisher’s exact test was used to compare HLA class I al-
lele frequencies between cohorts. The Mann–Whitney
paired test was used to compare the prevalence of HLA-
associated polymorphisms in the presence/absence of
their restricting HLA, in early versus chronic cohorts, as
these data were non-normally distributed. Pearson’s cor-
relation was used to investigate the relationship between
early escape prevalence and published first-year rates of
escape [13], as well as with published HLA allele-specific
Hazard Ratios for progression to AIDS [36], as these
data did not significantly violate the assumption that
values were drawn from a normal distribution. In single
analyses, significance is denoted by p < 0.05. In the case
of multiple tests, q-values are used [56]; thresholds are
defined throughout the paper. All tests of significance
were two-tailed.
Additional file
Additional file 1: A full summary of HLA-associated polymorphisms,
their HIV genomic locations and directions of association (adapted
vs nonadapted), and their observed frequencies in early versus
chronic infection in persons harboring vs. not harboring the
restricting HLA allele are provided in columns A-L and O-T. P-values
and q-values of association are also provided for early infection (Columns
M-N) and chronic infection (Columns U-V). P- and q-values comparing
the strength of selection of individual HLA-associated polymorphisms
between early and chronic stages are provided in Columns W-X. Finally,
all HLA-associated “adapted” polymorphisms are categorized with respect
to their relative timescale of escape (early vs. later; Column Y) as well as
their relative background frequency in the population (lower vs. higher;
Column Z).
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